Market Place
Sourcing Support
Cytokinetics Presents Additional Data From SEQUOIA-HCM Study
27 Sep 2024 //
GLOBENEWSWIRE
Research On VASCEPA To Be Presented At EASD Meeting
09 Sep 2024 //
GLOBENEWSWIRE
Cytokinetics Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
Cytokinetics Initiates Phase 1 Study Of Aficamten In Healthy Japanese
17 Jun 2024 //
GLOBENEWSWIRE
Cytokinetics secures up to $575M in royalty deal, frustrating investors
24 May 2024 //
BIOPHARMADIVE
Cytokinetics, Royalty Pharma Expand Collaboration Up To $575M
22 May 2024 //
GLOBENEWSWIRE
Cytokinetics Announces Five Aficamten Presentations At ESC Congress 2024
15 May 2024 //
GLOBENEWSWIRE
Cytokinetics looks to take on BMS’ Camzyos in hypertrophic cardiomyopathy
15 May 2024 //
CLINICALTRIALSARENA
Cytokinetics Pediatric HCM Trial CEDAR-HCM Starts
08 May 2024 //
GLOBENEWSWIRE
Cytokinetics Announces Positive Results From SEQUOIA-HCM
27 Dec 2023 //
GLOBENEWSWIRE
Cytokinetics Announces Start of ACACIA-HCM, a Phase 3 Trial of Aficamten
06 Sep 2023 //
GLOBENEWSWIRE
Aficamten Sets Cytokinetics Apart In Cardiomyopathy (CYTK)
10 Jul 2023 //
SEEKING ALPHA
Cytokinetics Announces Start of SEQUOIA-HCM Phase 3 Clinical Trial of Aficamten
23 Feb 2022 //
GLOBENEWSWIRE
Cytokinetics, Royalty partner on heart failure drug for $450M
08 Jan 2022 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.